clinical trial · NCT05288881
Single Ascending Dose Study of ANX105
HealthyANX105Placebo
brief summary
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ANX105 administered intravenously (IV) to healthy participants.
started
Feb 28, 2022
primary completion
Jun 19, 2023
completion
Jun 19, 2023
last updated
Aug 19, 2024
official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX105 in Normal Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol